By Anthony O. Goriainoff

AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.

The London-listed pharmaceutical giant said the first Phase 3 results showed a statistically-significant improvement in progression-free survival versus standard chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.

The company said datopotamab deruxtecan's safety profile is consistent with previous clinical trials and that no new safety signals identified.

"These first Phase 3 trial results from the datopotamab deruxtecan clinical program provide compelling evidence for the potential role this... antibody drug conjugate can play in treating patients with lung cancer," the company said.

Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

July 03, 2023 02:35 ET (06:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Daiichi Sankyo (PK) Charts.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Daiichi Sankyo (PK) Charts.